Abivax rejects short seller report on its obesity drug data
Abivax says the Scorpion Capital report contains numerous inaccurate statements and points to the fund's direct financial interest in a share price decline.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
French biotech Abivax issued a statement responding to a report published on November 20, 2026 by Scorpion Capital. The company says the report contains numerous factually inaccurate and misleading claims, including ones based on studies commissioned and funded by Scorpion Capital itself.
Abivax said it is reviewing the report in detail and expects to provide further updates. It also reaffirmed its confidence in the Phase 3 ABTECT trial results and said they will support the U.S. FDA NDA filing by the end of the year.
According to Abivax, Scorpion Capital openly disclosed its short position in the company and its intention to start covering a large part of it once the report was published.
why it matters
The statement matters mainly for holders of ABVX, since a short position gives the fund a direct interest in a lower share price. The story concerns a single company and has limited relevance for the broader market.
market impact
Abivax shares: short seller report and company rebuttal add uncertainty to the stock price
tags
instruments
sources
- Abivax Statement on Short Seller Report — globenewswire.com, 20 November 2026 at 21:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗